Researchers are looking for a better way to treat men at high-risk of biochemicalrecurrence (BCR) of prostate cancer.BCR means that in men who had prostate cancer and were treated by either surgery and/ orradiation therapy, the blood level of a specific protein called PSA rises. PSA is amarker of prostate cancer cells activity. The PSA increase means that the cancer has comeback even though conventional imaging such as computed tomography (CT) scans, magneticresonance imaging (MRI) and bone scans does not show any lesion of prostate cancer.Recently a more sensitive imaging method called prostate-specific membrane antigen [PSMA]positron emission tomography [PET]) /computed tomography [CT]) scan may identify prostatecancer lesions not detectable by conventional imaging. Men with BCR have a higher risk oftheir cancer spreading to other parts of the body, particularly when PSA levels raised toa certain limit within a short period of time after local therapies. Once the cancerspreads to ot
The purpose of this study is to evaluate whether the addition of darolutamide to ADT given for a pre-specified duration of 24 months provides superior efficacy compared with 24 months of placebo plus ADT based on radiological progression-free survival (rPFS) by prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)
